In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital
Medical Principles and Practice · 2024 · 33 (4) · 392-398
DOI: 10.1159/000538414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Principles and Practice, online erschienen am 20.03.2024. Verfasst von Sofia Maraki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece, sofiamaraki@yahoo.gr. Hauptthemen laut MEDLINE: Clostridioides difficile, Teicoplanin, Anti-Bacterial Agents, Clostridium Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Clostridioides difficile is a major cause of healthcare-associated diarrhea worldwide. For years, metronidazole and vancomycin were considered the standard treatment for C. difficile infection. However, they are increasingly being associated with treatment failure and recurrence. In this study, we investigated the in vitro activity of dalbavancin and fourteen other antimicrobials against 155 toxigenic C. difficile isolates originating from patients with C. difficile-associated diarrhea. Materials and Methods: Antimicrobial susceptibility was evaluated by the MIC Test Strip, and the results were interpreted using both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.
Results
C. difficile isolates were fully susceptible to metronidazole, vancomycin, amoxicillin/clavulanate, piperacillin/tazobactam, and tigecycline. All isolates were dalbavancin susceptible by the CLSI breakpoint (≤0.25 μg/mL) compared with 97.4% susceptibility by the EUCAST breakpoint (≤0.125 μg/mL). Dalbavancin demonstrated significantly lower MIC50 and MIC90 values compared to vancomycin (0.047 vs. 0.38 and 0.125 vs. 0.5, respectively, p < 0.001). Resistance rates to penicillin, ampicillin, cefoxitin, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, and tetracycline were 20%, 14.2%, 100%, 75.5%, 0.6%, 51%, 36.1%, 3.2%, and 14.8%, respectively. Multidrug-resistant phenotypes were detected among 41.3% of the isolates.
Conclusion
Dalbavancin exhibited potent activity against the isolates tested. As C. difficile is an important healthcare-associated pathogen, continued surveillance is required to monitor for development of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece, sofiamaraki@yahoo.gr.
- School of Medicine, University of Crete, Heraklion, Greece.
- Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece.
Zitieren
APA
Maraki, S., Mavromanolaki, V. E., Stafylaki, D., Iliaki-Giannakoudaki, E., & Kasimati, A. (2024). In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital. Medical Principles and Practice, 33(4), 392-398. https://doi.org/10.1159/000538414
Vancouver
Maraki S, Mavromanolaki VE, Stafylaki D, Iliaki-Giannakoudaki E, Kasimati A. In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital. Medical Principles and Practice. 2024;33(4):392-398. doi:10.1159/000538414
BibTeX
@article{Maraki2024,
author = {Maraki, Sofia and Mavromanolaki, Viktoria Eirini and Stafylaki, Dimitra and Iliaki-Giannakoudaki, Evangelia and Kasimati, Anna},
title = {In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital},
journal = {Medical Principles and Practice},
year = {2024},
volume = {33},
number = {4},
pages = {392--398},
doi = {10.1159/000538414}
}
EUVIMED